Copyright Reports & Markets. All rights reserved.

Global Polypeptide Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Polypeptide Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Synthetic Polypeptide Vaccines
    • 1.3.3 Recombinant Polypeptide Vaccine
    • 1.3.4 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Polypeptide Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Infectious Disease Prevention
    • 1.4.3 Cancer Immunotherapy
    • 1.4.4 Others
  • 1.5 Global Polypeptide Vaccine Market Size & Forecast
    • 1.5.1 Global Polypeptide Vaccine Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Polypeptide Vaccine Sales Quantity (2021-2032)
    • 1.5.3 Global Polypeptide Vaccine Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 AmbioPharm
    • 2.1.1 AmbioPharm Details
    • 2.1.2 AmbioPharm Major Business
    • 2.1.3 AmbioPharm Polypeptide Vaccine Product and Services
    • 2.1.4 AmbioPharm Polypeptide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 AmbioPharm Recent Developments/Updates
  • 2.2 Almac
    • 2.2.1 Almac Details
    • 2.2.2 Almac Major Business
    • 2.2.3 Almac Polypeptide Vaccine Product and Services
    • 2.2.4 Almac Polypeptide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Almac Recent Developments/Updates
  • 2.3 ACT
    • 2.3.1 ACT Details
    • 2.3.2 ACT Major Business
    • 2.3.3 ACT Polypeptide Vaccine Product and Services
    • 2.3.4 ACT Polypeptide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 ACT Recent Developments/Updates
  • 2.4 Ultimovacs
    • 2.4.1 Ultimovacs Details
    • 2.4.2 Ultimovacs Major Business
    • 2.4.3 Ultimovacs Polypeptide Vaccine Product and Services
    • 2.4.4 Ultimovacs Polypeptide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Ultimovacs Recent Developments/Updates
  • 2.5 Marker Therapeutics, Inc.
    • 2.5.1 Marker Therapeutics, Inc. Details
    • 2.5.2 Marker Therapeutics, Inc. Major Business
    • 2.5.3 Marker Therapeutics, Inc. Polypeptide Vaccine Product and Services
    • 2.5.4 Marker Therapeutics, Inc. Polypeptide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Marker Therapeutics, Inc. Recent Developments/Updates
  • 2.6 Immatics
    • 2.6.1 Immatics Details
    • 2.6.2 Immatics Major Business
    • 2.6.3 Immatics Polypeptide Vaccine Product and Services
    • 2.6.4 Immatics Polypeptide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Immatics Recent Developments/Updates
  • 2.7 OncoPep
    • 2.7.1 OncoPep Details
    • 2.7.2 OncoPep Major Business
    • 2.7.3 OncoPep Polypeptide Vaccine Product and Services
    • 2.7.4 OncoPep Polypeptide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 OncoPep Recent Developments/Updates
  • 2.8 Anergis
    • 2.8.1 Anergis Details
    • 2.8.2 Anergis Major Business
    • 2.8.3 Anergis Polypeptide Vaccine Product and Services
    • 2.8.4 Anergis Polypeptide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Anergis Recent Developments/Updates
  • 2.9 Sellas Life Sciences
    • 2.9.1 Sellas Life Sciences Details
    • 2.9.2 Sellas Life Sciences Major Business
    • 2.9.3 Sellas Life Sciences Polypeptide Vaccine Product and Services
    • 2.9.4 Sellas Life Sciences Polypeptide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Sellas Life Sciences Recent Developments/Updates

3 Competitive Environment: Polypeptide Vaccine by Manufacturer

  • 3.1 Global Polypeptide Vaccine Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Polypeptide Vaccine Revenue by Manufacturer (2021-2026)
  • 3.3 Global Polypeptide Vaccine Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Polypeptide Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Polypeptide Vaccine Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Polypeptide Vaccine Manufacturer Market Share in 2025
  • 3.5 Polypeptide Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 Polypeptide Vaccine Market: Region Footprint
    • 3.5.2 Polypeptide Vaccine Market: Company Product Type Footprint
    • 3.5.3 Polypeptide Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Polypeptide Vaccine Market Size by Region
    • 4.1.1 Global Polypeptide Vaccine Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Polypeptide Vaccine Consumption Value by Region (2021-2032)
    • 4.1.3 Global Polypeptide Vaccine Average Price by Region (2021-2032)
  • 4.2 North America Polypeptide Vaccine Consumption Value (2021-2032)
  • 4.3 Europe Polypeptide Vaccine Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Polypeptide Vaccine Consumption Value (2021-2032)
  • 4.5 South America Polypeptide Vaccine Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Polypeptide Vaccine Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Polypeptide Vaccine Sales Quantity by Type (2021-2032)
  • 5.2 Global Polypeptide Vaccine Consumption Value by Type (2021-2032)
  • 5.3 Global Polypeptide Vaccine Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Polypeptide Vaccine Sales Quantity by Application (2021-2032)
  • 6.2 Global Polypeptide Vaccine Consumption Value by Application (2021-2032)
  • 6.3 Global Polypeptide Vaccine Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Polypeptide Vaccine Sales Quantity by Type (2021-2032)
  • 7.2 North America Polypeptide Vaccine Sales Quantity by Application (2021-2032)
  • 7.3 North America Polypeptide Vaccine Market Size by Country
    • 7.3.1 North America Polypeptide Vaccine Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Polypeptide Vaccine Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Polypeptide Vaccine Sales Quantity by Type (2021-2032)
  • 8.2 Europe Polypeptide Vaccine Sales Quantity by Application (2021-2032)
  • 8.3 Europe Polypeptide Vaccine Market Size by Country
    • 8.3.1 Europe Polypeptide Vaccine Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Polypeptide Vaccine Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Polypeptide Vaccine Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Polypeptide Vaccine Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Polypeptide Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific Polypeptide Vaccine Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Polypeptide Vaccine Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Polypeptide Vaccine Sales Quantity by Type (2021-2032)
  • 10.2 South America Polypeptide Vaccine Sales Quantity by Application (2021-2032)
  • 10.3 South America Polypeptide Vaccine Market Size by Country
    • 10.3.1 South America Polypeptide Vaccine Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Polypeptide Vaccine Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Polypeptide Vaccine Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Polypeptide Vaccine Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Polypeptide Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa Polypeptide Vaccine Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Polypeptide Vaccine Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Polypeptide Vaccine Market Drivers
  • 12.2 Polypeptide Vaccine Market Restraints
  • 12.3 Polypeptide Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Polypeptide Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Polypeptide Vaccine
  • 13.3 Polypeptide Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Polypeptide Vaccine Typical Distributors
  • 14.3 Polypeptide Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Polypeptide Vaccine market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Polypeptide Vaccine is an anti-tumor therapeutic vaccine with the most researches, the best effect and the most mature technology among various therapeutic vaccines. Known as subunit vaccines, compared with traditional inactivated and attenuated vaccines, peptide vaccines can not only be used as preventive vaccines against infectious or non-infectious diseases, but also for the treatment of Alzheimer's disease, malignant tumors, etc.; peptide vaccines have become a new strategy for anti-tumor at present, and peptide anti-tumor therapeutic vaccines have accounted for the largest proportion of biotechnology anti-cancer new drugs under development.
    This report is a detailed and comprehensive analysis for global Polypeptide Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Polypeptide Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Polypeptide Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Polypeptide Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Polypeptide Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Polypeptide Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Polypeptide Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AmbioPharm, Almac, ACT, Ultimovacs, Marker Therapeutics, Inc., Immatics, OncoPep, Anergis, Sellas Life Sciences, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Polypeptide Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Synthetic Polypeptide Vaccines
    Recombinant Polypeptide Vaccine
    Others
    Market segment by Application
    Infectious Disease Prevention
    Cancer Immunotherapy
    Others
    Major players covered
    AmbioPharm
    Almac
    ACT
    Ultimovacs
    Marker Therapeutics, Inc.
    Immatics
    OncoPep
    Anergis
    Sellas Life Sciences
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Polypeptide Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Polypeptide Vaccine, with price, sales quantity, revenue, and global market share of Polypeptide Vaccine from 2021 to 2026.
    Chapter 3, the Polypeptide Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Polypeptide Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Polypeptide Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Polypeptide Vaccine.
    Chapter 14 and 15, to describe Polypeptide Vaccine sales channel, distributors, customers, research findings and conclusion.

    Buy now